Anaud A, et al. High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: a stepped-wedge cluster randomised controlled trial. Preprint [interim data/not peer reviewed] medRxiv 2020.09.06.20189308. Published September 8, 2020. Accessed March 14, 2021. doi: https://doi.org/10.1101/2020.09.06.20189308
Apple FS, Wu AHB, Sandoval Y, et al. Sex-specific 99th percentile upper reference limits for high sensitivity cardiac troponin assays derived using a universal sample bank. Clin Chem. 2020;66:434-444.
Bjurman D, Larsson M, Johanson P, et al. Small Changes in troponin T levels are common in patients with non–ST-segment elevation myocardial infarction and are linked to higher mortality. J Am Coll Cardiol. 2013;62:1231-1238.
Bularga A, Lee KK, Stewart S, et al. High-sensitivity troponin and the application of risk stratification thresholds in patients with suspected acute coronary syndrome. Circulation. 2019;140:1557-1568.
Chapman AR, Fijisawa T, Lee KK, et al. Novel high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syndrome. Heart 2019;105:616-622.
Chapman AR, Sandeman D, Ferry AV, et al. Risk stratification using high-sensitivity cardiac troponin T in patients with suspected acute coronary syndrome. J Am Coll Cardiol. 2020;75:985-987.
Collet JP, Thiele H, Barbato E, et al; ESC Scientific Document Group, 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), Eur Heart J. 2020. doi: 10.1093/eurheartj/ehaa575. [Epub ahead of print].
Shah A, Anand A, Strachan FE, et al. High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial. Lancet. 2018;392:919-928.
Shah AS, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015;386:2481-2848.
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802-810.
Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40;237-269.
Twerenbold R, Jaeger C, Rubini Gimenez M, et al. Impact of high-sensitivity cardiac troponin on use of coronary angiography, cardiac stress testing, and time to discharge in suspected acute myocardial infarction. Eur Heart J, 2016;37:3324–3332.
Wu AHB, Apple F, Love SA, et al; on behalf of the AACC's Biomarkers of acute cardiovascular disease division. creation of a universal sample bank for determining the 99th percentile for cardiac troponin assays. J Appl Lab Med. 2017;1:711-719.

CME / ABIM MOC

Recent Advances in Diagnostic Cardiology: Harnessing the Power of High-Sensitivity Troponin Assays

Authors: Allan Jaffe, MD; Nicholas Mills, MD, PhD
CME / ABIM MOC Released: 3/19/2021
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/19/2022, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for cardiologists, emergency medicine physicians, and primary care physicians.

The goal of this activity is to educate cardiologists about high-sensitivity cardiac troponin (hs-cTn) tests and how to use them effectively for timely diagnosis of acute myocardial infarction (AMI).

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- hs-cTn assays to detect AMI
Demonstrate greater confidence in their ability to
- Integrate hs-cTn assays into clinical practice

Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Allan Jaffe, MD

Professor of Cardiology
Professor of Laboratory Medicine and Pathology
Mayo Clinic
Rochester, Minnesota, United States

Disclosures

Disclosure: Allan Jaffe, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott; Amgen; Beckman-Coulter; ET Healthcare; Novartis; Radiometer; Roche; Siemens; Sphingotec

Nicholas Mills, MD, PhD

Chair of Cardiology
Consultant Cardiologist
BHF Butler Senior Clinical Research Fellow BHF Centre for Cardiovascular Sciences & Usher Institute
Edinburgh, United Kingdom

Disclosures

Disclosure: Nicholas Mills, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbott; Lumirax; Roche Diagnostics; Siemens Healthineers
Served as a speaker or a member of a speakers bureau for: Abbott; Lumirax; Roche Diagnostics; Siemens Healthineers
Received grants for clinical research from: Abbott

Steering Committee

Jerome Boursier, MD, PhD

University of Angers
Angers, France

Disclosures

Disclosure: Jerome Borsier, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol Myers Squibb; Echosens; Inventiva; Intercept Pharmaceuticals
Served as a speaker or a member of a speakers bureau for: Echosens; Eli Lilly; Gilead; Intercept Pharmaceuticals, Inc.; Siemens
Received grants for clinical research from: Intercept Pharmaceuticals, Inc.

Allan Jaffe, MD

Disclosures

As Seen Above

Phillip Levy, MD, MPH

Edward S. Thomas Professor and Associate Chair for Research
Department of Emergency Medicine
Assistant Vice President
Translation Science and Clinical Research and Innovation
Wayne State University
Detroit, Michigan, United States

Disclosures

Disclosure: Phillip Levy, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Baim Institute; Beckman Coulter; Ortho Clinical Diagnostics; Roche Diagnostics; Siemens

Nicholas Mills, MD, PhD

Disclosures

As Seen Above

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director, AdventHealth Diabetes Institute
Senior Investigatior and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins Scholl of Medicine
Baltimore, Maryland, United States

Disclosures

Disclosure: Richard E. Pratley, MD, has disclosed no relevant financial relationships.

Zobair M. Younossi, MD

Chairman
Inova Fairfax Hospital
Falls Church Virginia, United States

Disclosures

Disclosure: Zobair M. Younossi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol Myers Squibb; Gilead; Intercept; Merck; NovoNordisk; Novartis; Siemens; Terns; Viking

Editors

Cheryl Perkins, MD, RPh

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Cheryl Perkins, MD, RPh, has disclosed no relevant financial relationships.

Meghan Coulehan, MPH

Senior Director, Clinical Content Development, Medscape, LLC

Disclosures

Disclosure: Meghan Coulehan, MPH, has disclosed no relevant financial relationships.

Sowmya Daram, MPharm, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Sowmya Daram, MPharm, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:

Served as an advisor or consultant for: Abbott Labs

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME / ABIM MOC

Recent Advances in Diagnostic Cardiology: Harnessing the Power of High-Sensitivity Troponin Assays

Authors: Allan Jaffe, MD; Nicholas Mills, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 3/19/2021

Valid for credit through: 3/19/2022, 11:59 PM EST

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CME / ABIM MOC Information

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Allan Jaffe, MD

Nicholas Mills, MD, PhD

Steering Committee

Jerome Boursier, MD, PhD

Allan Jaffe, MD

Phillip Levy, MD, MPH

Nicholas Mills, MD, PhD

Richard E. Pratley, MD

Zobair M. Younossi, MD

Editors

Cheryl Perkins, MD, RPh

Meghan Coulehan, MPH

Sowmya Daram, MPharm, PhD

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

CME / ABIM MOC

Recent Advances in Diagnostic Cardiology: Harnessing the Power of High-Sensitivity Troponin Assays

Target Audience and Goal Statement

Disclosures

Faculty

Allan Jaffe, MD

Nicholas Mills, MD, PhD

Steering Committee

Jerome Boursier, MD, PhD

Allan Jaffe, MD

Phillip Levy, MD, MPH

Nicholas Mills, MD, PhD

Richard E. Pratley, MD

Zobair M. Younossi, MD

Editors

Cheryl Perkins, MD, RPh

Meghan Coulehan, MPH

Sowmya Daram, MPharm, PhD

CME Reviewer

Esther Nyarko, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Recent Advances in Diagnostic Cardiology: Harnessing the Power of High-Sensitivity Troponin Assays